Medios AG, a leading provider of Specialty Pharma in Europe, has announced the appointment of Katrin Neuffer as Director Investor Relations & Communications, effective immediately. Neuffer, who holds a degree in business administration and brings around 20 years of experience in capital markets communications, will oversee the company's interactions with investors, analysts, the media, and the public. She succeeds Claudia Nickolaus, who has played a pivotal role in shaping Medios' investor relations activities since the company's early days.
Neuffer's career includes significant roles at SDAX-listed Wacker Neuson SE, where she served as Head of Investor Relations & Corporate Communications from 2007 to 2018, guiding the company from its IPO to becoming a consistently attractive investment. She also led the Strategy and Sustainability departments there. Later, she headed an international team of 20 as Vice President Investor Relations & Corporate Communications and Marketing at Exyte Group, where she was responsible for preparing an IPO with a targeted market capitalization exceeding EUR 2 billion. Since 2020, she has worked as an independent consultant, supporting publicly listed companies in investor relations, IPO preparation, and crisis and restructuring communications.
Thomas Meier, CEO of Medios AG, expressed confidence in the new appointment: "With Katrin Neuffer, we are gaining a proven capital markets expert who has guided publicly listed companies through decisive phases of development, from IPOs to strategic repositioning. Her experience will help us reposition Medios in the capital markets and intensify our dialogue with investors, analysts, and the media." Meier also extended gratitude to Claudia Nickolaus for her years of dedication and professionalism in shaping Medios' capital markets communications.
The leadership change comes at a critical time for Medios, as the company prepares for several key events in the 2026 financial year. These include the half-year financial report on August 12, participation in the Berenberg and Goldman Sachs 15th German Corporate Conference in Munich from September 21 to 23, the Medios Capital Markets Day on September 28 and 29, and the quarterly statement on November 10. The appointment of a seasoned expert like Neuffer underscores Medios' commitment to strengthening its investor relations and enhancing transparency as it continues to grow in the specialty pharma sector.
Medios AG is Germany's first listed specialty pharmaceutical company, with shares listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and included in the SDAX selection index. The company operates across Germany, the Netherlands, Belgium, and Spain, focusing on pioneering individualized medicine to make innovative therapies accessible to patients, pharmacies, specialist practices, and pharmaceutical companies.
For more information about Medios and its initiatives, visit their website at www.medios.group and explore details on individualized medicine at app.medios.group/en/individualizedmedicine.
